Richa Parikh is an Oncology physician affiliated with Emory University. OpenAlex indexes 43 publications with 235 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20253 payments
- Janssen Biotech, Inc.Program year20254 payments
- Janssen Scientific Affairs, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
35.1%Potassium supplement35.1%Potassium Chloride100%Part D<11 patientsDermatology
35.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor35.1%Acyclovir100%Part D<11 patientsNervous system
29.7%Other nervous system drugs29.7%Vyndamax100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
2026 - PA-168 Efficacy and Safety of Linvoseltamab with Utilization of Outpatient Step-Up Dosing and Prophylactic Tocilizumab
Clinical Lymphoma Myeloma & Leukemia
2026 - Long-Term Progression-Free Survival in Patients Treated With RVD Induction and Risk-Adapted Maintenance
Clinical Lymphoma Myeloma & Leukemia
2026 - PA-327 Outcomes of Multiple Myeloma Patients with del17p with Coexistent Trisomy/Tetrasomy 17
Clinical Lymphoma Myeloma & Leukemia
2026
Similar KOLs
Other experts from the same institution or the same specialty.
James Lah, MD
Emory University
Vasilis Babaliaros, MD
Emory University
Keith Delman, MD
Emory University
John Puskas, MD
Emory University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”